CHO Plus was formed to address the high costs associated with therapeutic protein production.  CHO Plus technology addresses the high costs and capacity limitations associated with commercial therapeutic protein production.  We have developed patented technology for genetically engineering mammalian cells to improve productivity and enhance competitiveness for pharmaceutical company customers.  Proof-of-concept experiments demonstrate that CHO Plus engineered cells are 4.5-fold more productive than parent cells in a model system, validating our cell engineering approach.  CHO Plus will provide engineered cells for therapeutic protein production to pharmaceutical company customers in exchange for license fees plus royalties on product sales; customer benefits include lower capital spending for manufacturing facilities, lower COGS, and increased production capacity from existing manufacturing facilities.

CHO Plus has developed technology to genetically engineer mammalian cells to vastly improve therapeutic protein production. Cells are engineered to allow each cell to product much more protein than normally possible. US patent has been issued; PCT application has been filed.

Current $150 billion worldwide therapeutic protein market.

Industry-accepted technology licensing pricing model; 1% of gross product sales.

Anticipate rapid market share growth with $100 million revenues within 5 years with over 90% margins.

Anticipate company could be acquired at high ROI within 2 years after funding close.

CHO Plus raised seed funding from founders and angel investors. Funds were used to develop the technology, run successful proof-of-concept experiments, and to file for and receive a key US patent, and to file a PCT application.